Canada - français - Health Canada

lavo - hypochlorite de sodium - solution - 4.25% - hypochlorite de sodium 4.25% - disinfectants (for agents used on object)

Canada - français - Health Canada

oxi brite inc - chlorure de dioctyl-diméthyl ammonium; chlorure de didécyl-diméthyl ammonium; chlorure d'octyl décyl diméthyl ammonium; chlorure de benzalkonium - solution - 0.01995%; 0.01995%; 0.0399%; 0.0532% - chlorure de dioctyl-diméthyl ammonium 0.01995%; chlorure de didécyl-diméthyl ammonium 0.01995%; chlorure d'octyl décyl diméthyl ammonium 0.0399%; chlorure de benzalkonium 0.0532% - disinfectants (for agents used on object)

Canada - français - Health Canada

rockline industries - chlorure d'octyl décyl diméthyl ammonium; chlorure de dioctyl-diméthyl ammonium; chlorure de didécyl-diméthyl ammonium; chlorure de benzalkonium - serviette - 0.0909%; 0.0364%; 0.0545%; 0.1212% - chlorure d'octyl décyl diméthyl ammonium 0.0909%; chlorure de dioctyl-diméthyl ammonium 0.0364%; chlorure de didécyl-diméthyl ammonium 0.0545%; chlorure de benzalkonium 0.1212% - disinfectants (for agents used on object)

Cameroun - français - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

menarini international operations luxembourg - olmesartan medoxomil/amlodipine besilate - comprimé pelliculé/ film coated tablet - 40mg/5mg

Cameroun - français - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

menarini international operations luxembourg - olmesartan medoximil/amlodipine besilate - comprimé pelliculé/ film coated tablet - 40mg/10mg

Cameroun - français - DPML (Direction de la Pharmacie du Médicament et des Laboratoires)

menarini international operations luxembourg - olmesartan medoxomil/amlodipine besilate - comprimé pelliculé/ film coated tablet - 20mg/5mg

Canada - français - Health Canada

all clean natural ltd. - chlorure de benzalkonium - serviette - 0.13% - chlorure de benzalkonium 0.13%

Union européenne - français - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - pexidartinib - giant cell tumor of tendon sheath; synovitis, pigmented villonodular - agents antinéoplasiques - treatment of tenosynovial giant cell tumour.

Union européenne - français - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosuppresseurs - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires urgo soins & santé - nifuroxazide - gélule - 200 mg - composition pour une gélule > nifuroxazide : 200 mg - a07ax03 nifuroxazide